Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Consensus Rating of “Buy” from Analysts

Structure Therapeutics Inc. (NASDAQ:GPCR) has been assigned an average rating of “Buy” from the eight analysts that are presently covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $81.29.

A number of brokerages have recently commented on GPCR. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research report on Wednesday. They set a “buy” rating and a $50.00 price objective for the company. JMP Securities reiterated a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a report on Wednesday, December 18th. Morgan Stanley started coverage on shares of Structure Therapeutics in a research report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a research report on Thursday, December 19th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 target price on shares of Structure Therapeutics in a report on Monday, September 23rd.

Institutional Investors Weigh In On Structure Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in GPCR. Geode Capital Management LLC increased its position in Structure Therapeutics by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 45,225 shares of the company’s stock valued at $1,985,000 after acquiring an additional 312 shares during the period. Squarepoint Ops LLC increased its holdings in shares of Structure Therapeutics by 4.5% in the second quarter. Squarepoint Ops LLC now owns 14,449 shares of the company’s stock valued at $567,000 after purchasing an additional 617 shares during the period. Assetmark Inc. increased its holdings in shares of Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after purchasing an additional 719 shares during the period. Sandia Investment Management LP purchased a new stake in shares of Structure Therapeutics during the second quarter worth approximately $39,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after purchasing an additional 1,122 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Price Performance

GPCR opened at $27.04 on Thursday. The business has a fifty day moving average price of $32.63 and a 200 day moving average price of $36.70. Structure Therapeutics has a 12 month low of $25.90 and a 12 month high of $62.74. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -36.54 and a beta of -2.78.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.